BACKGROUND: Hormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. PURPOSE: To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk. STUDY TYPE: Retrospective. SUBJECTS: In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health). FIELD STRENGTH/SEQUENCE: Each subject underwent presurgical 3T breast MRI, which included DWI (b = 0, 800 s/mm2 ). ASSESSMENT: Apparent diffusion coefficient (ADC) and contrast-to-noise ratio (CNR) were measured for each lesion by a fifth year radiology resident. Pathological markers (Nottingham histologic grade, Ki-67, RS) were determined from pathology reports. Medical records were reviewed to assess recurrence-free survival. STATISTICAL TESTS: RS was stratified into low (<18), moderate (18-30), and high (>30)-risk groups. Associations of DWI characteristics with pathologic biomarkers were evaluated by binary or ordinal logistic regression, as appropriate, with adjustment for multiple comparisons. Post-hoc comparisons between specific groups were also performed. RESULTS: ADCmean (odds ratio [OR] = 0.61 per 1 standard deviation [SD] increase, adj. P = 0.044) and CNR (OR = 1.76 per 1-SD increase, adj. P = 0.026) were significantly associated with increasing tumor grade. DWI CNR was also significantly associated with a high (Ki-67 ≥14%) proliferation rate (OR = 2.55 per 1-SD increase, adj. P = 0.026). While there were no statistically significant linear associations in ADC (adj. P = 0.80-0.85) and CNR (adj. P = 0.56) across all three RS groups by ordinal logistic regression, post-hoc analyses suggested that high RS lesions exhibited lower ADCmean (P = 0.037) and ADCmax (P = 0.004) values and higher CNR (P = 0.008) compared to lesions with a low or moderate RS. DATA CONCLUSION: DWI characteristics correlated with tumor grade, proliferation index, and RS, and may potentially help to identify those with highest recurrence risk and most potential benefit from chemotherapy. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage 3 J. Magn. Reson. Imaging 2017.
BACKGROUND:Hormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. PURPOSE: To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk. STUDY TYPE: Retrospective. SUBJECTS: In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health). FIELD STRENGTH/SEQUENCE: Each subject underwent presurgical 3T breast MRI, which included DWI (b = 0, 800 s/mm2 ). ASSESSMENT: Apparent diffusion coefficient (ADC) and contrast-to-noise ratio (CNR) were measured for each lesion by a fifth year radiology resident. Pathological markers (Nottingham histologic grade, Ki-67, RS) were determined from pathology reports. Medical records were reviewed to assess recurrence-free survival. STATISTICAL TESTS: RS was stratified into low (<18), moderate (18-30), and high (>30)-risk groups. Associations of DWI characteristics with pathologic biomarkers were evaluated by binary or ordinal logistic regression, as appropriate, with adjustment for multiple comparisons. Post-hoc comparisons between specific groups were also performed. RESULTS: ADCmean (odds ratio [OR] = 0.61 per 1 standard deviation [SD] increase, adj. P = 0.044) and CNR (OR = 1.76 per 1-SD increase, adj. P = 0.026) were significantly associated with increasing tumor grade. DWI CNR was also significantly associated with a high (Ki-67 ≥14%) proliferation rate (OR = 2.55 per 1-SD increase, adj. P = 0.026). While there were no statistically significant linear associations in ADC (adj. P = 0.80-0.85) and CNR (adj. P = 0.56) across all three RS groups by ordinal logistic regression, post-hoc analyses suggested that high RS lesions exhibited lower ADCmean (P = 0.037) and ADCmax (P = 0.004) values and higher CNR (P = 0.008) compared to lesions with a low or moderate RS. DATA CONCLUSION: DWI characteristics correlated with tumor grade, proliferation index, and RS, and may potentially help to identify those with highest recurrence risk and most potential benefit from chemotherapy. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage 3 J. Magn. Reson. Imaging 2017.
Authors: M Costantini; P Belli; P Rinaldi; E Bufi; G Giardina; G Franceschini; G Petrone; L Bonomo Journal: Clin Radiol Date: 2010-09-24 Impact factor: 2.350
Authors: Elizabeth S McDonald; Jennifer G Schopp; Sue Peacock; Wendy B DeMartini; Wendy D DeMartini; Habib Rahbar; Constance D Lehman; Savannah C Partridge Journal: AJR Am J Roentgenol Date: 2014-05 Impact factor: 3.959
Authors: Elizabeth J Sutton; Jung Hun Oh; Brittany Z Dashevsky; Harini Veeraraghavan; Aditya P Apte; Sunitha B Thakur; Joseph O Deasy; Elizabeth A Morris Journal: J Magn Reson Imaging Date: 2015-04-07 Impact factor: 4.813
Authors: Habib Rahbar; Brenda F Kurland; Matthew L Olson; Averi E Kitsch; John R Scheel; Xiaoyu Chai; Joshua Usoro; Constance D Lehman; Savannah C Partridge Journal: J Comput Assist Tomogr Date: 2016 May-Jun Impact factor: 1.826
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Tao Wan; B Nicolas Bloch; Donna Plecha; CheryI L Thompson; Hannah Gilmore; Carl Jaffe; Lyndsay Harris; Anant Madabhushi Journal: Sci Rep Date: 2016-02-18 Impact factor: 4.379
Authors: Marco Macchini; Martina Ponziani; Andrea Prochowski Iamurri; Mirco Pistelli; Mariagrazia De Lisa; Rossana Berardi; Gian Marco Giuseppetti Journal: Radiol Med Date: 2018-06-05 Impact factor: 3.469
Authors: Jin You Kim; Jin Joo Kim; Lee Hwangbo; Ji Won Lee; Nam Kyung Lee; Kyung Jin Nam; Ki Seok Choo; Taewoo Kang; Heeseung Park; Yohan Son; Robert Grimm Journal: Eur Radiol Date: 2019-08-05 Impact factor: 5.315
Authors: Alexey Surov; Paola Clauser; Yun-Woo Chang; Lihua Li; Laura Martincich; Savannah C Partridge; Jin You Kim; Hans Jonas Meyer; Andreas Wienke Journal: Breast Cancer Res Date: 2018-06-19 Impact factor: 6.466
Authors: Alexey Surov; Yun-Woo Chang; Lihua Li; Laura Martincich; Savannah C Partridge; Jin You Kim; Andreas Wienke Journal: BMC Cancer Date: 2019-11-05 Impact factor: 4.430
Authors: Ioannis Tsougos; Alexandros Vamvakas; Constantin Kappas; Ioannis Fezoulidis; Katerina Vassiou Journal: Comput Math Methods Med Date: 2018-09-23 Impact factor: 2.238